---
title: "Vivani Medical: Buy Rating Reaffirmed as Novo Nordisk Evaluation and Cortigent–ClearOne Merger Support $3.50 Price Target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292224424.md"
description: "H.C. Wainwright analyst Yi Chen reaffirmed a Buy rating on Vivani Medical with a $3.50 price target, citing strategic validation from Novo Nordisk's evaluation of its NPM-139 semaglutide implant and the planned merger of Vivani’s Cortigent unit with ClearOne. These developments support capital efficiency and potential future collaboration. Maxim Group also reiterated a Buy rating with a $4.00 target."
datetime: "2026-07-09T16:25:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292224424.md)
  - [en](https://longbridge.com/en/news/292224424.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292224424.md)
generator: "portal-rs"
---

# Vivani Medical: Buy Rating Reaffirmed as Novo Nordisk Evaluation and Cortigent–ClearOne Merger Support $3.50 Price Target

Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on Vivani Medical. The associated price target is $3.50.

### 4th of July Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Yi Chen has given his Buy rating due to a combination of factors that highlight both strategic validation and upside potential for Vivani Medical. The newly signed agreement allowing Novo Nordisk to run an internal, non-exclusive evaluation of Vivani’s NPM-139 semaglutide implant is viewed as a meaningful external endorsement of the NanoPortal platform, especially since semaglutide is a key asset for Novo with patent protection expiring in 2032, creating an incentive to explore long-acting lifecycle extensions.

Yi Chen’s rating is based on the expectation that successful Phase 1 data for NPM-139, targeted to begin in mid-2026 with readout by year-end, could pave the way for a deeper collaboration with Novo and unlock significant value. In addition, the planned merger of Vivani’s Cortigent unit with Nasdaq-listed ClearOne is expected to lower Vivani’s direct spending on Cortigent while preserving a majority equity stake in the combined entity, supporting both capital efficiency and continued participation in Cortigent’s future growth, which underpins the reaffirmed Buy rating and $3.50 price target.

In another report released yesterday, Maxim Group also reiterated a Buy rating on the stock with a $4.00 price target.

### Related Stocks

- [CRGT.US](https://longbridge.com/en/quote/CRGT.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)
- [VANI.US](https://longbridge.com/en/quote/VANI.US.md)
- [CLRO.US](https://longbridge.com/en/quote/CLRO.US.md)
- [NVOX.US](https://longbridge.com/en/quote/NVOX.US.md)

## Related News & Research

- [ClearOne Q2 FY26 net loss from continuing operations narrows to $919,000; general and administrative expense falls 22% to $849,000](https://longbridge.com/en/news/295974471.md)
- [Vivani Medical posts investor deck outlining NanoPortal ultra-long-acting GLP-1 implant strategy for obesity market](https://longbridge.com/en/news/296142116.md)
- [ClearOne Grants Equity to Advisors for Merger Support](https://longbridge.com/en/news/295591452.md)
- [Mitsui to supply e-methanol to OMV for land transport fuel under RFNBO deal](https://longbridge.com/en/news/296423772.md)
- [UBS Reaffirms Their Buy Rating on SIG Group AG (SCBGF)](https://longbridge.com/en/news/296203907.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**